{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:14:08Z","timestamp":1793038448391,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Gallbladder carcinoma (GBC) is responsible for 80%\u201395% of biliary tract malignancies and has a dismal prognosis. Human epidermal growth factor receptor 2 (HER2) is a promising therapeutic target of GBC. Through immunohistochemistry (IHC) and fluorescence <jats:italic>in situ<\/jats:italic> hybridization (FISH) methods, HER2 expression and gene amplification were identified on high-output tissue microarrays (TMAs) developed in 306 GBC cases to investigate its relationship with GBC and clinicopathological characteristics. Adenocarcinomas accounted for 223 (72.9%) of the cases, with 62 (27.8%) being papillary adenocarcinoma or having partial papillary structure. HER2 positivity was studied in 16.1% (36\/223) of patients with adenocarcinoma and 41.9% (26\/62) in adenocarcinoma with papillary structures. For 143 radically resected primary GBC cases with 24 HER2-positive tumors, survival data were valid; the median survival time was not reached, and the 5-year survival rate was 52.9%. All patients in stages 0\u2013I survived, and the results of the HER2-positive group and the stage II HER2-negative group were similar (<jats:italic>p<\/jats:italic> = 0.354). However, in stage III, the mortality rate in the HER2-positive group was reduced (<jats:italic>p<\/jats:italic> = 0.005) and that in stage IV was higher (<jats:italic>p<\/jats:italic> = 0.005). In conclusion, HER2 positivity was significantly higher in patients with papillary GBC. The predictive value of HER2 varies by clinical stage, with no prediction in the early stages, better in stage III, and worse in stage IV.<\/jats:p>","DOI":"10.3389\/fgene.2021.831318","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T07:05:37Z","timestamp":1643958337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Lingli","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongkui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00428-019-02706-6","article-title":"HER2 Gene (ERBB2) Amplification Is a Low-Frequency Driver with Potential Predictive Value in Gallbladder Carcinoma","volume":"476","author":"Albrecht","year":"2020","journal-title":"Virchows Arch."},{"key":"B2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s0140-6736(10)61121-x","article-title":"Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal junction Cancer (ToGA): a Phase 3, Open-Label, Randomised Controlled Trial","volume":"376","author":"Bang","year":"2010","journal-title":"The Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1309\/8a2djft07ne6ewhe","article-title":"Detection and Quantitation of HER-2 Gene Amplification and Protein Expression in Breast Carcinoma","volume":"122","author":"Bofin","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1471-2407-6-126","article-title":"Preliminary Study of P53 and C-erbB-2 Expression in Gallbladder Cancer in Indian Patients","volume":"6","author":"Chaube","year":"2006","journal-title":"BMC cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1080\/15384047.2015.1113356","article-title":"Molecular Profiling of 6,892 Colorectal Cancer Samples Suggests Different Possible Treatment Options Specific to Metastatic Sites","volume":"16","author":"El-Deiry","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in Gastric Cancer: a New Prognostic Factor and a Novel Therapeutic Target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/jco.2017.75.3780","article-title":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results from MyPathway, an Open-Label, Phase IIa Multiple Basket Study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"Jco"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3748\/wjg.15.4511","article-title":"EGFR and HER2 Expression in Advanced Biliary Tract Cancer","volume":"15","author":"Harder","year":"2009","journal-title":"Wjg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","article-title":"Details of Human Epidermal Growth Factor Receptor 2 Status in 454 Cases of Biliary Tract Cancer","volume":"105","author":"Hiraoka","year":"2020","journal-title":"Hum. Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 Scoring System for Gastric Cancer: Results from a Validation Study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/modpathol.3880007","article-title":"Determination of Her-2\/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization","volume":"13","author":"Jimenez","year":"2000","journal-title":"Mod. Pathol."},{"key":"B12","first-page":"221","article-title":"HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer","volume":"1","author":"Kawamoto","year":"2007","journal-title":"Gastrointest. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0171280","DOI":"10.1371\/journal.pone.0171280","article-title":"The Frequency and Clinical Impact of HER2 Alterations in Lung Adenocarcinoma","volume":"12","author":"Kim","year":"2017","journal-title":"PloS one"},{"key":"B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0377-4929.94862","article-title":"Role of C-erbB2 Expression in Gallbladder Cancer","volume":"55","author":"Kumari","year":"2012","journal-title":"Indian J. Pathol. Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","article-title":"Epidemiology and Molecular Pathology of Gallbladder Cancer","volume":"51","author":"Lazcano-Ponce","year":"2001","journal-title":"CA: a Cancer J. clinicians"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/s0140-6736(16)32417-5","article-title":"HER2-positive Breast Cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"The Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3892\/or.11.4.815","article-title":"Gallbladder Cancers Rarely Overexpress HER-2\/neu, Demonstrated by Hercep Test","volume":"11","author":"Matsuyama","year":"2004","journal-title":"Oncol. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1078-0432.ccr-18-2275","article-title":"Advances in HER2-Targeted Therapy: Novel Agents and Opportunities beyond Breast and Gastric Cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/s1470-2045(03)01021-0","article-title":"Carcinoma of the Gallbladder","volume":"4","author":"Misra","year":"2003","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00428-015-1720-0","article-title":"Microsatellite Instability in Gallbladder Carcinoma","volume":"466","author":"Moy","year":"2015","journal-title":"Virchows Arch."},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy502","article-title":"Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients with Metastatic Gastric Cancer: a JSMO-ESMO Initiative Endorsed by CSCO, KSMO, MOS, SSO and TOS","volume":"30","author":"Muro","year":"2019","journal-title":"Ann. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/path.1779","article-title":"Amplification and Overexpression of C-erbB-2,epidermal Growth Factor Receptor, and C-Met in Biliary Tract Cancers","volume":"206","author":"Nakazawa","year":"2005","journal-title":"J. Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1007\/s00464-018-6138-8","article-title":"Clinicopathological Features and Endoscopic Findings of HER2-Positive Gastric Cancer","volume":"32","author":"Oono","year":"2018","journal-title":"Surg. Endosc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/ajg.2009.411","article-title":"Expression of p21(Wafl\/Cip1), p57(Kip2) and HER2\/neu in Patients with Gallbladder Cancer","volume":"27","author":"Puhalla","year":"2007","journal-title":"Anticancer Res."},{"key":"B25","first-page":"42","article-title":"Overexpression of the HER2\/neu Gene: A New Therapeutic Possibility for Patients with Advanced Gallbladder Cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.humpath.2009.10.002","article-title":"Epidermal Growth Factor Receptor and HER-2\/neu Status by Immunohistochemistry and Fluorescence In Situ Hybridization in Adenocarcinomas of the Biliary Tree and Gallbladder","volume":"41","author":"Shafizadeh","year":"2010","journal-title":"Hum. Pathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1746-1596-8-9","article-title":"An Alternative High Output Tissue Microarray Technique","volume":"8","author":"Shi","year":"2013","journal-title":"Diagn. Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/nejmoa0910383","article-title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/nejm200103153441101","article-title":"Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1440-1827.2005.01831.x","article-title":"Comparison between Immunohistochemistry and Chromogenic In Situ Hybridization in Assessing HER-2 Status in Breast Cancer","volume":"55","author":"Todorovic-Rakovic","year":"2005","journal-title":"Pathol. Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3748\/wjg.v18.i11.1208","article-title":"Expression of HER2 and Bradykinin B1receptors in Precursor Lesions of Gallbladder Carcinoma","volume":"18","author":"Toledo","year":"2012","journal-title":"Wjg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and Gemcitabine for Advanced Biliary Tract Cancer: a Meta-Analysis of Two Randomised Trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 Screening Data from ToGA: Targeting HER2 in Gastric and Gastroesophageal junction Cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/annonc\/mds528","article-title":"Her2\/neu Testing in Gastric Cancer: Evaluating the Risk of Sampling Errors","volume":"24","author":"Warneke","year":"2013","journal-title":"Ann. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"87699","DOI":"10.18632\/oncotarget.21181","article-title":"The Prognostic Significance of MCL1 Copy Number Gain in Esophageal Squamous Cell Carcinoma","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1615\/jenvironpatholtoxicoloncol.2017025229","article-title":"Dual Roles of Oxidative Stress in Metal Carcinogenesis","volume":"36","author":"Xu","year":"2017","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB Signalling Network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cel Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00428-015-1898-1","article-title":"A Significant Subgroup of Resectable Gallbladder Cancer Patients Has an HER2 Positive Status","volume":"468","author":"Yoshida","year":"2016","journal-title":"Virchows Arch."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.cell.2007.04.034","article-title":"FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2\/ErbB2 Oncogene","volume":"129","author":"Zuo","year":"2007","journal-title":"Cell"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.831318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:17:44Z","timestamp":1645442264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.831318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":39,"alternative-id":["10.3389\/fgene.2021.831318"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.831318","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"article-number":"831318"}}